Quotes 5-day view Delayed London Stock Exchange
10/21/2020
10/22/2020
10/23/2020
10/26/2020
10/27/2020
Date
7920(c)
7955(c)
7943(c)
8077(c)
8056 Last
1 410 226
1 467 484
999 438
1 245 512
1 514 561 Volume
-1.81% +0.44% -0.15% +1.69% -0.26% Change
Sales 2020
26 684 M - -
Net income 2020
3 050 M - -
Net Debt 2020
13 182 M - -
P/E ratio 2020
48,7x
Yield 2020
2,68%
Sales 2021
30 229 M - -
Net income 2021
4 423 M - -
Net Debt 2021
11 281 M - -
P/E ratio 2021
33,8x
Yield 2021
2,71%
Capitalization
138 B 138 B -
EV / Sales 2020
5,66x
EV / Sales 2021
4,94x
Nbr of Employees
70 600
Free-Float
95,7%
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows:
- oncology (36.8%);
- respiratory diseases (22.9%);
- cardiovascular, renal and metabolic diseases (18.6%);
- other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases.
Net sales are distributed geographically as follows: the United...
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
All news about ASTRAZENECA PLC
News in other languages on ASTRAZENECA PLC
Analyst Recommendations on ASTRAZENECA PLC
AstraZeneca : says its Oxford vaccine deal allows it to add up to 20% of manufacturing costs
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ASTRAZENECA PLC
Short Term Mid-Term Long Term Trends Bearish Bearish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
25
Average target price
118,34 $
Last Close Price
105,12 $
Spread / Highest target
47,9%
Spread / Average Target
12,6%
Spread / Lowest Target
-37,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
